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Abstract
Background: We developed and validated a new and simple metric, the Programmatic Compliance Score (PCS), based on
the IAS-USA antiretroviral therapy management guidelines for HIV-infected adults, as a predictor of all-cause mortality, at a
program-wide level. We hypothesized that non-compliance would be associated with the highest probability of mortality.
Methods and Findings: 3543 antiretroviral-naive HIV-infected patients aged $19 years who initiated antiretroviral therapy
between January 1, 2000 and August 31, 2009 in British Columbia (BC), Canada, were followed until August 31, 2010. The PCS is
composed by six non-performance indicators based on the IAS-USA guidelines: (1) having,3 CD4 count tests in the first year
after starting antiretroviral therapy; (2) having,3 plasma viral load tests in the first year after starting antiretroviral therapy; (3)
not having drug resistance testing done prior to starting antiretroviral therapy; (4) starting on a non-recommended
antiretroviral therapy regimen; (5) starting therapy with CD4,200 cells/mm3; and (6) not achieving viral suppression within 6
months since antiretroviral therapy initiation. The sum of these six indicators was used to develop the PCS score - higher score
indicates poorer performance. The main outcomewas all-cause mortality. Each PCS component was independently associated
with mortality. In the mortality analysis, the odds ratio (OR) for PCS $4 versus 0 was 22.37 (95% CI 10.46–47.84).
Conclusions: PCS was strongly associated with all-cause mortality. These results lend independent validation to the IAS-USA
treatment guidelines for HIV-infected adults. Further efforts are warranted to enhance the PCS as a means to further
improve clinical outcomes. These should be specifically evaluated and targeted at healthcare providers and patients.
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Introduction
HIV treatment has evolved tremendously since the advent of
highly active antiretroviral therapy (HAART) in 1996 [1–9]. The
goal of HAART is to decrease HIV-related morbidity and
mortality through sustained full suppression of viral replication
(i.e. plasma viral load ,50 copies/mL). More recently, HAART
has also been recognized as a highly effective strategy to prevent
HIV transmission [10]. Definitive confirmation of the efficacy of
HIV treatment as prevention was provided by the recent results of
the HPTN 052 trial [11]. In this study, immediate use of HAART
was shown to decrease HIV transmission by 96%. This has
generated a renewed enthusiasm in the global roll out of HAART
[12,13]. However, it is still not clear which metrics, at the
individual and the population levels, should be used to monitor
and evaluate the impact of this powerful intervention.
HIV treatment guidelines provide evidence-based standards
aimed to optimize the management of HIV infected individuals.
However, for a variety of reasons, not all patients are fully
adherent to these guidelines. Here, we developed and validated a
composite metric, the Programmatic Compliance Score, to assess
the impact of non-compliance with HIV treatment guidelines on
all-cause mortality, among antiretroviral therapy-treated HIV-
infected individuals within a fully subsidized, population-based
antiretroviral therapy program. We hypothesized that non-
compliance would be associated with the highest chance of dying
prematurely.
Methods
Ethical Approval
The Centre’s HIV/AIDS Drug Treatment program has
received ethical approval from the University of British Columbia
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Ethics Review Committee at its St. Paul’s Hospital site. The
program also conforms with the province’s Freedom of Informa-
tion and Protection of Privacy Act.
HIV Patients on Treatment in British Columbia
This study was conducted using population data from the
British Columbia (BC) Centre for Excellence in HIV/AIDS (the
Centre) [7]. The Centre’s guidelines have remained consistent
with recommendations of the IAS-USA since 1996 and up to the
latest guidelines in 2010 [1–9]. The details of this program have
been described elsewhere [14]. In BC, medical and laboratory
monitoring, including specialized tests such as CD4 cell counts,
plasma viral load, genotypic resistance testing are all fully
subsidized. The Centre has received ethical approval from the
University of British Columbia Ethics Review Committee at the St
Paul’s Hospital site.
Study Population
Eligible study participants were $19 years old, naı¨ve to
antiretroviral therapy when they started treatment between
January 1, 2000 and August 31, 2009. These patients were
followed until death due to any cause, or if alive, until the last
contact date or August 31, 2010, whichever came first. Finally, to
be eligible for this analysis, participants were required to have at
least one baseline CD4 cell count and a plasma viral load
measurement available within six months prior to the antiretro-
viral starting date.
Laboratory Data
All plasma viral load measurements in BC are centrally done at
the St Paul’s Hospital virology laboratory. The quantification
range of plasma viral load assays has evolved over time, as
previously described. Thus, for analytical purposes, we truncated
our measurements to range from ,50 to .100,000 copies/mL.
CD4 cell counts are measured by flow cytometry, followed by
fluorescent monoclonal antibody analysis (Beckman Coulter, Inc.,
Mississauga, Ontario, Canada). The CD4 data come from
different laboratories across BC, and, in our database, we capture
.80% of all CD4 tests done in the province. HIV genotypic
resistance testing is performed centrally at the Centre’s laboratory.
Samples have been assigned to one of four resistance categories
based on a modification of the 2011 IAS-USA list of mutations
[15].
Antiretroviral Regimen
The recommended antiretroviral therapy regimens have
changed since 2000, based on the BC guidelines for treating
HIV-positive adults, as in the IAS-USA guidelines [4–9].
Therefore, we developed rules to classify regimes as contemporary
appropriate or not, as described in the Supplementary text.
The Programmatic Compliance Score
We developed six performance indicators based on the IAS-
USA guideline recommendations during 2000–2010 [4–9]: (1)
Having ,3 (coded as 1) or $3 (coded as 0) CD4 cell count
measurements in the first year after starting antiretroviral therapy;
(2) Having ,3 (coded as 1) or $3 (coded as 0) plasma viral load
measurements in the first year after starting antiretroviral therapy;
(3) Having a genotypic resistance test performed (coded as 0) or
not (coded as 1) at baseline; (4) Initiating antiretroviral therapy
with baseline CD4 cell count with,200 cells/mm3 (coded as 1) or
$200 cells/mm3 (coded as 0); (5) Initiating antiretroviral therapy
on a combination regimen recommended by contemporary
guidelines (coded as 0) or not (coded as 1); and (6) Achieving
viral suppression within 6 months of initiating antiretroviral
therapy (coded as 0) or not (coded as 1). Viral suppression was
defined by two consecutive plasma viral loads ,50 copies/mL.
Our main measure of exposure, the programmatic compliance
score (PCS), was then obtained by adding the values for indicators
1 to 6, which provided a range from 0 (least compliance) to 6 (most
non-compliance).
Outcome Measure and Statistical Analyses
The primary outcome in this study was all-cause mortality.
Deaths occurring during the follow-up period were identified on a
continuous basis through record linkages carried out with the BC
Division of Vital Statistics and enhanced by direct physician
reports to the program.
Further, we considered the following baseline explanatory
variables: age, gender, history of injection drug use (IDU), year
of antiretroviral therapy initiation, plasma viral load, follow-up
time in months and place of residence at the start of antiretroviral
therapy. Place of residence was used to control for the
heterogeneity in patient treatment access, care and socio-
demographic factors not previously defined. We also considered
adherence to antiretroviral therapy measured at 12 months from
antiretroviral therapy initiation, since the calculation of adherence
at 6 months in our database can yield less precise estimates.
Adherence was estimated by dividing the number of months of
medications dispensed by the number of months of follow-up. We
have previously shown that this measure of adherence is
independently associated with HIV viral suppression and survival
[16–18]. Adherence was categorized as either ,95% or $95%.
We run two sets of analysis. The first set included data from
patients who have started antiretroviral therapy between 2000 and
2009. The second analysis, recognizing that some of the variables
were not collected systematically before the year 2006, we
restricted our analysis from patients who have started antiretro-
viral therapy between 2006 and 2009.
In bivariable analyses, categorical variables were compared
using the Fisher’s exact test, and continuous variables were
compared using the Wilcoxon rank-sum test. The mortality
probability model was built in terms of finding the best predictive
probabilistic model of mortality, using logistic regression [19].
First, we drew a random sample without replacement from the
original data, splitting the original data in half. One half was used
as a training dataset, in which we built the multivariable logistic
model and assessed its fit by calculating the area under the receiver
operating characteristic curve. This area was used to assess the
model’s ability to discriminate between those who died versus
those who did not. A backward stepwise technique was used in the
selection of covariates to build this model. The selection of
variables was based on two criteria: Akaike Information Criterion
(AIC) and Type III p-values. These two criteria balance the model
choice by finding the best explanatory model (Type III p-values
based on the Type III Sum of Squares, with lower p-values
indicate more significance) and at the same time a model with the
best goodness-of-fit statistic (AIC – lower values indicate better fit).
At each step of this process, the AIC value and the Type III p-
values of each variable were recorded, and the variable with the
highest Type III p-value was dropped, until there are no more
variables left. The final model has the lowest AIC. The second half
of the data was used to assess whether the predictions based on the
coefficients obtained from the analysis on the training dataset were
valid or not. For goodness of fit, we calculated the mean squared
error, the mean absolute error and the Wilcoxon rank-sum test.
Kaplan-Meier method with log-rank test was used for the
The PCS Score and HAART Outcomes
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comparison of the unadjusted survival rates. All analyses were
performed using SAS software version 9.2 (SAS, Cary, NC).
Results
Cohort Characteristics
A total of 3543 antiretroviral naı¨ve adults (79% males) were
eligible to participate in this study. At baseline, the median age was
42 years (25th to 75th percentile range [Q1–Q3]: 35–48 years),
CD4 cell count was 190 cells/mm3 (Q1–Q3: 100–280 cells/mm3),
and plasma viral load was 4.9 log10 copies/mL (Q1–Q3: 4.4–5.0
log10 copies/mL). The median follow-up was 44 months (Q1–Q3:
22–77 months). Of these patients, 39% had a history of IDU, 52%
started antiretroviral therapy before 2006, and 63% were more
than 95% adherent during the first year of follow-up.
Programmatic Compliance Score (PCS)
At baseline, 42% of patients did not receive a genotypic
resistance test before therapy initiation, 11% of patients received a
non-recommended antiretroviral therapy regimen, and 52% of
patients had a baseline CD4 count ,200 cells/mm3. During the
first year of follow-up, 23% of patients had fewer than 3 CD4
count tests done, 16% had ,3 plasma viral load tests done, and
46% did not achieve viral suppression within 6 months of
beginning treatment. After several exploratory analyses, we
decided to group the PCS as 0, 1, 2, 3 and 4 or more. The
distribution of PCS was, then: 16% for a 0 score, 26% for a score
of 1, 27% for a score of 2, 16% for a score of 3 and 14% for scores
of 4 or more. Figure 1 shows the distribution of PCS over time,
and as we moved from 2000 to 2009, individuals starting
antiretroviral therapy on the later years were more likely to have
a PCS score of 0 (p-value for trend ,0.0001).
Predictive Mortality Probability Model (Follow-Up from
2000 to 2010)
At the end of follow-up, 499 (14%) deaths were recorded,
producing an overall crude death rate of 33 per 1000 person-years.
Table 1 shows the bivariable association of our main exposure,
indicators and baseline factors with all cause mortality. Those who
have died were more likely to be older (44 versus 41 years; p-
value,0.0001), to have a shorter follow-up (23 versus 47 months;
p-value,0.0001), to have a history of IDU (18% versus 11%; p-
value,0.0001), to have adherence ,95% during the first year on
antiretroviral therapy (21% versus 10%; p-value,0.0001), and to
have started antiretroviral therapy during 2000–2005 (21% versus
7% p-value,0.0001). All six indicators were strongly associated
with all cause mortality, and therefore, those with a PCS $4 were
more likely to have died in this study (38% versus 20%, 12%, 7%
and 2% for scores 3, 2, 1 and 0, respectively; p-value,0.0001).
Table 2 shows the Kaplan Meier estimates for the mortality
probability by levels of the PCS score. As expected, those
individuals with a PCS $4 were at a much higher probability of
mortality throughout the study period (log-rank test p-val-
ue,0.0001), with the crude mortality estimate ranging from 0%
(SE 60%) for PCS = 0 to 20.7% (SE 61.8%) for PCS $4 at 6
months to 1.1% (SE 60.5%) for PCS = 0 to 30.2% (SE 62.2%)
for PCS $4 at 30 months. To predict the probability of mortality
for each patient in our study, we present the coefficients in Table 3.
The measures used to assess the goodness of fit of our predictive
model indicated that we have obtained a really well fitted model.
Thus, the odds ratio (OR) for PCS from 1, 2, 3, 4 or more versus 0
were, respectively, 3.81 (95% CI 1.73–8.42), 7.97 (95% CI 3.70–
17.18), 11.51 (95% CI 5.28–25.08), and 22.37 (95% CI 10.46–
47.84). We were also interested in assessing the importance of each
component in the PCS score on the probability of mortality and
the strongest influence related to failing to suppress plasma viral
load at 6 months (OR 4.25; 95% CI 3.15–5.75; area under the
curve 0.668), having ,3 plasma viral load tests during the first
year (OR: 4.68; 95%CI 3.49–6.28; area under the curve 0.638)
and having no resistance test done at baseline (OR: 2.40; 95%CI
1.83–3.15; area under the curve 0.608).
Sensitivity Analysis
This analysis was restricted to the individuals who have started
antiretroviral therapy between 2006 and 2009. In total, we
observed 118 deaths (7%), producing an overall crude death rate
of 30 per 1000 person-years. Table 4A shows the association of
each component of the PCS score and all cause-mortality.
Differently from the original analysis, the top three PCS
components most influential on the probability of mortality were
having ,3 plasma viral load tests during the first year (OR: 7.54;
95%CI 5.10–11.16; area under the curve 0.691), failing to
suppress plasma viral load at 6 months (OR: 4.66; 95%CI 3.04–
7.14; area under the curve 0.680) and starting on a non-
Figure 1. Distribution of the programmatic compliance score over time.
doi:10.1371/journal.pone.0047859.g001
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Table 1. Descriptive statistics by mortality status at the end of follow-up.
Deceased at the End of Follow-up
List of Variables No Yes p-value
N=3044 N=499
Programmatic Compliance Score
0 565 (98%) 13 (2%) ,0.0001
1 868 (93%) 68 (7%)
2 845 (88%) 111 (12%)
3 449 (80%) 114 (20%)
4 or more 317 (62%) 193 (38%)
Age
Median 41 44 ,0.0001
Q1–Q3 35–48 37–51
Follow-up (in months)
Median 47 23 ,0.0001
Q1–Q3 25–82 6–48
Gender
Male 2431 (86%) 385 (14%) 0.1692
Female 613 (84%) 114 (16%)
Injection drug use history
No 1918 (89%) 248 (11%) ,0.0001
Yes 1126 (82%) 251 (18%)
Adherence during first year
$95% 2008 (90%) 216 (10%) ,0.0001
,95% 1036 (78%) 283 (21%)
Year of first ARV
2000–2005 1455 (79%) 381 (21%) ,0.0001
2006–2010 1589 (93%) 118 (7%)
Number of CD4 cell count measurements (1st year)
$3 2412 (89%) 309 (11%) ,0.0001
,3 632 (77%) 190 (23%)
Number of plasma HIV-1 RNA level measurements (1st year)
$3 2665 (90%) 303 (10%) ,0.0001
,3 379 (66%) 196 (34%)
Baseline resistance test
Yes 1871 (91%) 184 (9%) ,0.0001
No 1173 (79%) 315 (21%)
Baseline CD4 cell count (cells/mm3)
$200 1535 (91%) 157 (9%) ,0.0001
,200 1509 (81%) 342 (18%)
Recommended HAART regimen
Yes 2718 (87%) 422 (13%) ,0.0001
No 326 (81%) 77 (19%)
Suppression at 6 month
Yes 1789 (93%) 127 (7%) ,0.0001
No 1255 (77%) 372 (23%)
Health Region
Vancouver Coastal HA - City Center 1961 (88%) 273 (12%) ,0.0001
Vancouver Coastal HA - DTES 196 (78%) 55 (22%)
Vancouver Coastal HA - Other 265 (90%) 31 (10%)
The PCS Score and HAART Outcomes
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recommended antiretroviral therapy (OR: 3.78; 95%CI 2.49–
5.75; area under the curve 0.657). The multivariable model fitted
for this analysis aimed at finding whether PCS explains the risk of
mortality, while adjusting for the same covariates as in the case of
the original analysis (Table 4B). The OR for PCS from 1, 2, 3, 4 or
more versus 0 were, respectively, 3.02 (95% CI 1.16–7.89), 5.01
(95% CI 1.92–13.06), 9.02 (95% CI 3.44–23.64), and 15.77 (95%
CI 6.28–39.61).
Discussion
Using various indicators of non-compliance to treatment
guidelines, we developed a simple and highly predictive metric,
the Programmatic Compliance Score or PCS, to predict the
probability of mortality among HIV-positive individuals starting
naı¨ve on antiretroviral therapy. We found that individuals who
had a PCS score 4 or higher had a mortality probability 22 times
higher than those individuals with PCS score 0. The sensitivity
analysis also confirmed these results. The PCS, therefore, may
serve as a simple but powerful proxy for the performance of the
Table 1. Cont.
Deceased at the End of Follow-up
List of Variables No Yes p-value
N=3044 N=499
Interior HA 118 (83%) 25 (17%)
Fraser HA 170 (80%) 42 (20%)
Vancouver Island HA 266 (82%) 60 (18%)
Northern HA 68 (84%) 13 (16%)
Notes: HA: Health Authority, Q1: 25th percentile; Q3: 75th percentile.
doi:10.1371/journal.pone.0047859.t001
Table 2. Kaplan Meier estimates for the probability of mortality by the levels of the programmatic compliance score.
List of Variables Follow-up Log-rank Test
12 months 18 months 24 months 30 months p-value
Number of CD4 cell count measurements (1st year)
$3 2.5% (60.3%) 3.9% (60.4%) 4.8% (60.4%) 6.1% (60.5%) ,0.0001
,3 12.9% (61.1%) 14.5% (61.2%) 15.8% (61.3%) 17.0% (61.3%)
Number of plasma HIV-1 RNA level measurements (1st year)
$3 1.9% (60.3%) 3.1% (60.3%) 4.1% (60.4%) 5.2% (60.4%) ,0.0001
,3 20.4% (61.6%) 23.1% (61.8%) 24.6% (61.8%) 26.4% (61.9%)
Baseline resistance test
Yes 3.6% (60.4%) 4.4% (60.5%) 5.0% (60.5%) 5.9% (60.5%) ,0.0001
No 7.2% (60.7%) 9.4% (60.8%) 10.9% (60.8%) 12.6% (60.9%)
Baseline CD4 cell count (cells/mm3)
$200 2.2% (60.4%) 3.1% (60.4%) 3.9% (60.5%) 4.9% (60.6%) ,0.0001
,200 7.8% (60.6%) 9.8% (60.7%) 10.9% (60.7%) 12.4% (60.8%)
Recommended cART regimen
Yes 3.2% (60.5%) 4.5% (60.5%) 4.6% (60.6%) 5.2% (60.7%) 0.0125
No 6.2% (60.5%) 8.0% (60.6%) 9.2% (60.6%) 10.7% (60.7%)
Suppression at 6 month
Yes 0.9% (60.2%) 1.6% (60.3%) 2.1% (60.3%) 2.8% (60.4%) ,0.0001
No 9.9% (60.7%) 12.2% (60.8%) 13.8% (60.9%) 15.7% (60.9%)
Programmatic Compliance Score
0 0.4% (60.3%) 0.8% (60.4%) 0.8% (60.4%) 1.1% (60.5%)
1 0.7% (60.3%) 1.4% (60.4%) 1.9% (60.5%) 2.6% (60.6%)
2 1.8% (60.4%) 3.0% (60.6%) 4.0% (60.7%) 5.0% (60.7%) ,0.0001
3 7.6% (61.1%) 10.3% (61.1%) 12.3% (61.4%) 14.8% (61.6%)
4 or more 23.6% (61.9%) 26.7% (62.0%) 28.4% (62.1%) 30.2% (62.3%)
doi:10.1371/journal.pone.0047859.t002
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program as a whole in achieving execution of its accepted
guidelines. The PCS incorporates the overall effects of the
decisions and social situations of patients, physicians and others
in whether or not treatment guidelines are actually implemented.
It is noteworthy and surprising that indicators associated with
plasma viral load and resistance were far more impactful than
suboptimal CD4 cell count at the start of therapy with respect to
the probability of mortality. Low CD4 cell count at the start of
antiretroviral therapy has been shown by our group and by others
to be highly predictive of adverse treatment outcomes [20–22].
Closer monitoring of patients during their first year on antiretro-
viral therapy, especially plasma viral load, can increase the
chances of these individuals to fully benefit from this life-saving
therapy at the short- and long terms. The reasons for poor patient
monitoring practices are not clear, especially in an environment in
which HIV treatment, care and laboratory monitoring are fully
subsidized. Further efforts are warranted to explore possible
reasons for this at the health care provider and patient levels. This
in turn may assist in the development of specific strategies to
enhance the PCS as a means to further improve clinical outcomes.
These should be specifically evaluated and targeted to health care
providers as well as HIV infected clients. Furthermore, our results
provide important clues on how to develop effective strategies to
improve HIV associated health outcomes not only in BC, but
around the world.
There are several features of our study that should be
highlighted. First, this study was based on patients who were
naı¨ve to antiretroviral therapy, thus our results were not
confounded by previous therapy use. Secondly, despite the
potential limitations of using pharmacy refill-based adherence as
a surrogate marker of actual pill taking, we have previously shown
that this measure of adherence is independently associated with
different disease outcomes [16–18]. Thirdly, delayed reporting of
deaths or incomplete data collection are not likely an issue with
this analysis, since all deaths were reported within three months of
death through active follow-up with physicians and hospitals and
regular linkages to BC Vital Statistics Agency. Fourthly, even
though the guidelines prior to 2006 did not explicitly say that
baseline resistance should be done prior to starting antiretroviral
therapy, we decided to include this indicator in our PCS score
because transmitted drug resistance has always been one of the
factors that affect future disease outcomes. The PCS score is not
an indicator to penalize healthcare providers, but it serves to
identify areas in our treatment program that should be improved.
It is important to look at temporal trends (2000–2009) so we can
identify which indicators have improved and those that have not.
Due to missing data in some of the indicators present in the PCS
score for patients starting antiretroviral therapy during 2000–
2005, we re-run the analysis including only data from patients who
started antiretroviral therapy after the year 2006. Baseline
resistance testing continued to be an important indicator of
programmatic compliance. Fifthly, we acknowledge that the
model only uses information collected during the first year on
therapy, and not information on the subsequent years to predict
the risk of mortality. The first year on antiretroviral therapy is
really important in a patient’s treatment history. If these
individuals are not properly managed in the first year, we believe
that it is likely that they will not be managed properly thereafter.
Thus, the PCS score was developed so that we want to catch
individuals with high risk of mortality due to improper disease
management in the beginning of treatment, and we want to
identify the areas in which our program that can be improved.
Sixthly, one of the indicators in our PCS score is baseline CD4 cell
count. Some may argue that is not a measure of non-compliance,
Table 3. Results from the predictive model for the probability of mortality based on the programmatic compliance score.
Variables Necessary to Estimate the Probability of Mortality Maximum Likelihood Estimates
Coefficient
Standard
Deviation
Odds Ratio (95%
Confidence Interval) Type III P-value
Programmatic Compliance Score
0 0.0 0.0 1(-) ,0.0001
1 1.3387 0.4042 3.81 (1.73–8.42)
2 2.0761 0.3916 7.97 (3.70–17.18)
3 2.4434 0.3974 11.51 (5.28–25.08)
4 or more 3.1079 0.3878 22.37 (10.46–47.84)
Also Adjust Model for:
Intercept 24.4132 0.5039 ,0.0001
Age (in years) 0.0324 0.00742 1.03 (1.02–1.05) ,0.0001
History of Injection Drug Use (Yes:1; No: 0) 0.5298 0.153 1.70 (1.26–2.29) 0.0005
Follow-up time in Months 20.0242 0.00265 0.98 (0.97–0.98) ,0.0001
Goodness-of-fit Training Dataset
Akaike Information Criterion 1185.551
Area under the Receiver Operating Curve 0.801
Goodness-of-fit Validation Dataset
Mean Squared Error 0.274
Mean Absolute Error 0.361
Wilcoxon Rank Sum Test p-value ,0.0001
doi:10.1371/journal.pone.0047859.t003
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but rather a biological measure of disease severity. Based on the
cascade of care framework, individuals who have tested positive
for HIV should be monitored from the time they get their positive
test result until the time they become eligible to receive
antiretroviral therapy. In BC, as in many other places around
the world, over the years, we have lost many patients in this period
of time. These individuals lost to follow-up after they test positive
have most often showed up in our emergence departments with,
sometimes, a CD4 cell count almost close to zero. This is
completely unacceptable. Thus, CD4 cell count at antiretroviral
presentation is an indicator of the performance of our system, and
not only a biological indicator. Seventhly, although we adjusted
our analyses for several demographic and clinical characteristics,
as in all observational studies unmeasured differences may exist
among study populations, and for this reason, our findings should
be interpreted cautiously. Finally, given that this study was
conducted at the population-level within a fully subsidized medical
system where antiretroviral therapy as well as medical and
laboratory monitoring are free of charge to all participants, we
are confident that our results are less likely to be biased by direct
financial limitations to access to health services, a frequent
confounder in cohort and population based studies.
In summary, the Programmatic Compliance Score or PCS
metric is highly predictive of all-cause mortality, among HIV
infected adults starting antiretroviral therapy. Our results show
that individuals with sub-optimal PCS compliance are at a very
high probability of premature morbidity and mortality. It is
important to mention that the requirement for having a baseline
genotypic testing before starting antiretroviral therapy was not
explicitly stated in the guidelines prior to 2006, and only
Table 4. Relationship between the programmatic compliance score and mortality.
(A)
Bivariable Analysis
List of Variables Odds Ratio (95% Confidence Interval) Area Under the Curve
Number of CD4 cell count measurements (1st year)
$3 1(-) 0.649
,3 3.87 (2.65–5.67)
Number of plasma HIV-1 RNA level measurements (1st year)
$3 1(-) 0.691
,3 7.54 (5.10–11.16)
Baseline resistance test
Yes 1(-) 0.594
No 2.49 (1.69–3.67)
Baseline CD4 cell count (cells/mm3)
$200 1(-) 0.527
,200 1.85 (1.04–3.28)
Recommended HAART regimen
Yes 1(-) 0.657
No 3.78 (2.49–5.75)
Suppression at 6 month
Yes 1(-) 0.680
No 4.66 (3.04–7.14)
(B)
Model for the Probability of Mortality Odds Ratio (95% Confidence Interval) Type III P-value
Programmatic Compliance Score
0 1(-)
1 3.02 (1.16–7.89)
2 5.01 (1.92–13.06) ,0.0001
3 9.02 (3.44–23.64)
4 or more 15.77 (6.28–39.61)
Also Adjust Model for:
Age (in years) 1.07 (1.05–1.09) ,0.0001
History of Injection Drug Use (Yes:1; No: 0) 2.35 (1.48–3.74) 0.0003
Follow-up time in Months 0.91 (0.89–0.93) ,0.0001
(A) Bivariable associations between each of programmatic compliance score components and mortality for individuals who started antiretroviral therapy between 2006
and 2009. (B) Results from the multivariable explanatory model for the probability of mortality based on the programmatic compliance score for individuals who started
antiretroviral therapy between 2006 and 2009. Area Under the Curve: 0.896.
doi:10.1371/journal.pone.0047859.t004
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emphasized in the guidelines after 2006. However, given that the
efficacy of antiretroviral therapy is directly related to having a fully
functional regimen, there is no reason for failing to order such an
important test, given that it is free for anyone starting antiretroviral
therapy in BC. Thus, while these results do not allow us to
establish a causal relationship regarding the association between
our new metric and survival, this metric highlights the importance
of adherence to treatment and monitoring guidelines during the
first year on antiretroviral therapy. Despite improvement in the
PCS within our cohort over time, it is clear that there is still
substantial room for improvement. It should be emphasized that
minimizing the occurrence of these non-compliance practices is
not solely dependent on the healthcare provider. Health admin-
istrative bodies can improve compliance outcomes through regular
surveillance and ongoing physician training. Further, the individ-
ual patient ultimately bears responsibility for his/her own health;
the implications of poor compliance to treatment need to be
communicated at the time of initiation. Furthermore, our results
provide important clues on how to develop effective strategies to
improve HIV associated health outcomes not only in BC, but
around the world. Finally, our results also lend independent
validation to the most recent IAS-USA antiretroviral therapy
management guidelines for HIV infected adults.
Supporting Information
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